Lopinavir/ritonavir for high-grade anal disease in adults
Treatments studied
Part of Cancer, Infections clinical trials.
This early-phase study (Phase 1) tests how safe and tolerable the medicine lopinavir/ritonavir is for adults with HIV and biopsy-confirmed high-grade anal dysplasia. It may help find a possible treatment option for people at higher risk, while also checking for side effects and whether the study plan can be followed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have HIV and a biopsy-confirmed diagnosis of high-grade anal dysplasia (HGAIN)
- Be willing and able to sign informed consent
- Be able to follow the study visits and procedures
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
This study is looking at ways to screen for anal cancer in people who are at higher risk, such as those with weakened immune systems or a history of abnormal cells in the lower genital tract. It aims to find better methods for early detection.
This trial tests a prevention program for anal cancer in men who have sex with men who are at higher risk, such as those with HIV or taking PrEP. It aims to find and treat early signs of anal cancer to stop it from developing.
This study looks at using a simple swab to screen for HPV (the virus that can cause anal cancer) in people living with HIV. By collecting a sample from the anal area, the study aims to find a less invasive way to check for risk, helping you avoid more uncomfortable procedures unless needed.
This trial tests a gel called ACU-D1 for treating high-grade precancerous lesions caused by HPV in the vulvar or perianal area. The goal is to see if the gel can help clear these lesions in people living with HIV.
Hear when a new High-Grade Anal Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.